Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

liver fibrosis

News and Trends 9 Jan 2023

Alentis reports positive results from fibrosis study

Alentis Therapeutics has announced positive results from a single ascending dose phase 1 study of its lead program, ALE.F02, currently in development for the treatment of advanced kidney, lung and liver fibrosis. The study found ALE.F02 to be well tolerated in healthy volunteers at all doses with a good safety profile and demonstrated initial evidence […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

Novartis

News and Trends 9 Jan 2023

STALICLA signs agreement with Novartis on neurodevelopmental disorders

STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

CAR-T

News and Trends 9 Jan 2023

New biomarker for early prediction of response to CAR-T cell therapy

A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. The results of the study were recently published […]

January 9, 2023 - 4 minutesmins - By Jim Cornall

non-small cell lung cancer NSCLC

News and Trends 6 Jan 2023

Transgene approved for IV oncolytic virus trial

Transgene has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I clinical trial of TG6050. TG6050 is a novel oncolytic virus (OV) that will be administered intravenously in patients with advanced non-small cell lung cancer (NSCLC). Transgene is […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

Beyond Biotech podcast 28

News and Trends 6 Jan 2023

Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals

This week, we have two guests. We have conversations with Newron CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler. Mainz Biomed year-end corporate review Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022. The company launched […]

January 6, 2023

merger acquisition M&A

News and Trends 6 Jan 2023

Ensoma acquiring Twelve Bio

Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced that portfolio company Twelve Bio will be acquired by Ensoma in connection with an $85 million financing of Ensoma which Arix co-led, investing $9 million. Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT

tumor tumour

News and Trends 6 Jan 2023

C2i Genomics extends AstraZeneca cancer deal

C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

peptide

News and Trends 6 Jan 2023

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

Orbit Discovery Limited has entered into a master service agreement with SanegeneBio Inc., a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. The agreement covers activities ranging from hit ID to cell-based […]

January 6, 2023 - 2 minutesmins - By Jim Cornall

inest tumor analysis

News and Trends 6 Jan 2023

BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies

BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […]

January 6, 2023 - 4 minutesmins - By Jim Cornall

Anastasiia Slynko cancer CAR macrophage

In Depth 5 Jan 2023

Navignostics maps tumor proteomes to improve precision oncology

New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […]

January 5, 2023 - 4 minutesmins - By Jonathan Smith

CRISPR gene editing

News and Trends 5 Jan 2023

Researchers discover new type of CRISPR gene scissors

Scientists at the Helmholtz Institute Würzburg in Germany, and Benson Hill, Inc. (Missouri) and Utah State University in the U.S., have found a nuclease, which they dubbed Cas12a2, that represents an entirely new type of CRISPR immune defense. Unlike any other previously known nuclease of the CRISPR-Cas immune system, the source of ‘gene scissors,’ Cas12a2 […]

January 5, 2023 - 4 minutesmins - By Jim Cornall

cancer

News and Trends 5 Jan 2023

Cancer Research UK and Turbine to partner on program

Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT